TD DEVELOPPEMENT - T2D

What TD DEVELOPPEMENT - T2D does

T2D.com, operated by T2D Inc. (a Delaware corporation and wholly-owned subsidiary of Vertical Insight Corp), is a US-based digital health platform serving type 2 diabetics and pre-diabetics. The company delivers an integrated subscription service that combines licensed prescriber evaluation, compounded GLP-1 medications (Semaglutide and Tirzepatide) sourced through vetted US compounding pharmacies and manufacturers, ongoing monitoring, pharmacy coordination, and temperature-controlled home delivery via UPS/FedEx.

The platform is built on AWS infrastructure with native iOS and Android applications and uses Stripe for subscription billing. The product surface bundles clinical access, dispensing, and logistics into a single recurring engagement, positioning the business as a vertically integrated cash-pay alternative to branded GLP-1 therapies. Service is currently limited to US residents only, reflecting regulatory and supply-chain constraints around compounded peptides.

T2D.com operates as a direct-to-consumer business with no enterprise channel disclosed. The company was founded by four co-founders — Sean Sullivan (CEO), James Beams (CTO), Scott Hengst (SVP Sales), and Alec Ogletree (strategic investor and former NFL player) — with corporate backing from Vertical Insight Corp, a healthcare and insurance technology holding entity. No external funding rounds, revenue figures, or headcount beyond the founding team have been disclosed.

Note on conflicting inputs: the firmographics record describes TD DEVELOPPEMENT - T2D as a French business and management consulting firm in Revel, France founded in 2020. This contradicts the dominant first-party evidence (website content, team, technology, products, legal entity, and parent company), which consistently identifies T2D as a US digital health platform. The analysis above follows the first-party, more recent, and more specific sources per the documented conflict-resolution precedence.

Name

TD DEVELOPPEMENT - T2D

Legal name

T2D Inc.

Website

https://t2d.com

Company type

Private

Founded year

2020

Operating status

Operating

Short description

T2D.com is a US-based digital health platform serving type 2 diabetics and pre-diabetics with an integrated subscription service combining licensed prescriber access, compounded GLP-1 medications (Semaglutide and Tirzepatide), pharmacy coordination, and home delivery. It operates as a subsidiary of Vertical Insight Corp.

Ownership category

akta.pro rank

Product category

Telehealth Diabetes Care

NAICS

Other Ambulatory Health Care Services (6219), Pharmacies and Drug Retailers (45611)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)

akta.pro secondary industries

Type 2 Diabetes Care (HLAKADAC), Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)

Keywords

• Digital health platform
• Telehealth diabetes care
• GLP-1 medication delivery
• Compounded Semaglutide service
• Prescription subscription

Headquarters

HQ city

Revel

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

1. Subscription Service - Complete Medication Program: Monthly subscription model where customers pay a recurring fee for access to the complete service including prescriber evaluation, medication (compounded Semaglutide or Tirzepatide), pharmacy coordination, ongoing monitoring, and home delivery. Payment is processed automatically via Stripe on a recurring basis until cancellation.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

T2D.com sells a monthly subscription "Complete Service with Prescriber" for U.S. type 2 diabetics and pre-diabetics that bundles a licensed telehealth prescriber evaluation, compounded Semaglutide or Tirzepatide medication, pharmacy coordination, ongoing monitoring, and direct home delivery in a single integrated offering. Customers self-register on t2d.com or the iOS/Android apps, complete an online prescriber evaluation, and receive temperature-controlled medication shipped via UPS or FedEx.

Product overview

T2D.com is a digital healthcare services platform for type 2 diabetics and pre-diabetics that offers a unified complete service model combining licensed prescriber access, compounded GLP-1 medications (Semaglutide and Tirzepatide), pharmacy coordination, ongoing monitoring, and direct-to-home delivery. The company provides its services through a website (T2D.com) and iOS/Android mobile applications, offering medications in partnership with licensed pharmacies and USA-based pharmaceutical manufacturers. The core offering is the "Complete Service with Prescriber" which integrates everything from prescription to delivery in one seamless solution. Additionally, T2D.com provides an educational Medication Knowledge Base featuring comparative content about various GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound, and their compounded alternatives.

Differentiator

Problem solved

Functional benefit

Products and services

• Complete Service with Prescriber An all-in-one integrated monthly subscription healthcare service for U.S. type 2 diabetics and pre-diabetics that bundles a licensed telehealth prescriber evaluation, compounded Semaglutide or Tirzepatide medication, pharmacy coordination, ongoing treatment monitoring, and temperature-controlled home delivery via UPS or FedEx into a single seamless offering accessed via t2d.com or the iOS/Android apps.
• Compounded Semaglutide Compounded Semaglutide medication available through the T2D.com Complete Service, delivered directly to U.S. patients' homes in temperature-controlled packaging via UPS or FedEx, with prescriber evaluation determining patient appropriateness as part of the integrated subscription.
• Compounded Tirzepatide Compounded Tirzepatide medication available through the T2D.com Complete Service, delivered directly to U.S. patients' homes in temperature-controlled packaging via UPS or FedEx, with prescriber evaluation determining patient appropriateness as part of the integrated subscription.

Quantifiable outcome

• GLP-1 medications shown to reduce risk of stroke, heart attack, and cardiovascular death in diabetics
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Amazon Web Services (AWS)coreTechnology or IntegrationThe T2D.com website is hosted by Amazon Web Services (AWS), providing the cloud infrastructure for the digital health platform and services.
• Stripe Inc.coreTechnology or IntegrationStripe Inc. provides billing and payment processing services for the company's subscription-based revenue model. T2D does not itself collect or store payment card information.
• Licensed Pharmacies (Contracted)coreStrategic or Co-development PartnerT2D.com contracts directly with highly vetted, fully licensed pharmacies to fulfill compounded Semaglutide and Tirzepatide prescriptions. These pharmacy partners work directly with prescribers as part of the integrated service.
• USA-based Pharmaceutical ManufacturerscoreStrategic or Co-development PartnerT2D.com contracts with USA-based pharmaceutical manufacturers that have a sincere interest in serving the needs of type 2 diabetics, ensuring supply chain reliability and medication quality.
• HIPAA-Approved Data Security and Compliance FirmssupportingTechnology or IntegrationT2D.com is contracted with HIPAA-approved respected data security and compliance firms to provide protection for customer health information and ensure regulatory compliance.

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Amazon Pharmacy: Amazon Pharmacy is a large-scale online pharmacy offering prescription fulfillment, home delivery, and integrated clinician services. While not GLP-1-specialized, it is a broad incumbent in DTC prescription fulfillment that competes for the same prescription-delivery economics as T2D.
• GoodRx: GoodRx operates a prescription drug marketplace and telehealth service offering discounted medications and provider consultations. It competes more broadly across chronic prescription access rather than specializing in T2D/GLP-1, but overlaps with T2D on cash-pay pharmacy and telehealth.
• Eli Lilly (LillyDirect): Eli Lilly, the manufacturer of Mounjaro and Zepbound, launched LillyDirect, a direct-to-patient channel for its branded GLP-1s. As the upstream drug producer with captive supply, it represents both a competitor for any branded pivot and a major industry incumbent shaping the channel.

Direct peers

• Ro: Ro operates a DTC telehealth platform with its Ro Body program offering GLP-1 medications (including compounded Semaglutide), online prescriber consultations, and home delivery. It mirrors T2D's vertically integrated, cash-pay approach to GLP-1 access.
• LifeMD: LifeMD runs a DTC telehealth platform including its LifeMD+ weight management program that offers compounded Semaglutide with tele-prescribing and home delivery, directly comparable to T2D's integrated service offering.
• Noom: Noom launched Noom Med, a telehealth-based prescription GLP-1 program bundled with its behavior-change platform. It competes with T2D on chronic-condition patient acquisition, prescriber integration, and recurring-subscription economics.
• Found Health: Found is a DTC telehealth platform focused on weight management, offering GLP-1 prescribing, coaching, and ongoing care on a subscription basis. It overlaps directly with T2D on chronic-condition telehealth, prescription delivery, and integrated prescriber care.
• WeightWatchers: WeightWatchers acquired Sequence to launch its WW GLP-1 Program, providing telehealth consultations and prescription GLP-1 access to subscribers. It directly competes with T2D in cash-pay, subscription-based GLP-1 delivery for chronic-condition management.
• Sesame: Sesame operates a cash-pay telehealth and prescription marketplace offering direct booking with clinicians and weight-loss prescriptions including GLP-1s, comparable to T2D's direct-to-consumer online prescriber and dispensing model.
• Hims & Hers Health: Hims & Hers Health is a major DTC telehealth platform that sells compounded GLP-1 medications (Semaglutide) and prescription weight-loss programs through its Hers brand, closely matching T2D's direct-to-consumer model, cash-pay subscription pricing, and integrated prescriber + pharmacy workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TD DEVELOPPEMENT - T2D